science meets medicine: acute promyelocytic leukemia
Post on 11-Jan-2016
33 Views
Preview:
DESCRIPTION
TRANSCRIPT
SCIENCE MEETS MEDICINE:ACUTE PROMYELOCYTIC
LEUKEMIA
Nancy Fuller, M.D.June 23, 2004
• Objectives:1. Understand the history and presentation
of Acute Promyelocytic Leukemia (APL)2. Be familiar with the major abnormalities
and genetic factors 3. Understand treatment and prognostic
indicators4. Be amazed at the achievements gained
with the interaction between basic sciences and clinical medicine.
• Disclosure:No outside sources of funding (and
inside sources getting smaller all the time)
25 yo woman presented to clinic in May
-3 week history of spontaneous bruising, increasing fatigue, and dizziness with minor exertion like climbing stairs.
-1 nose bleed 3 weeks ago, none since; no bleeding from gums or per rectum
PMH: previously healthy except for history of an eating disorder several years ago, now asymptomatic
-on no meds; she had taken aspirin on a couple of occasions in the recent past because of headaches.
-LMP 2 weeks before, heavier than usual
-New sexual partner for past 6 weeks
PE: slim young woman in NAD, VS normal
HEENT: no petechia or bleedingPulm: normal CV: II/VI murmurAbd: splenomegaly, no hepatomegalyExt: multiple eccymoses especially
over lower legs but also upper legs, arms. No petechia noted
Labs: WBC: 2.4 (27% PMN, 23% lymph,
47% blasts, 2% NRBC H/H: 10.6/29 PLTS 18 K LFTs normal, INR 1.2 Fibrinogen 147 (165-400) D-Dimer greater than 18 (0-0.5)
Differential: consistent with acute promyelocytic leukemia (atypical promyelocytes with folded or dumb-bell shaped nuclei; large granules, and Auer rods)
Bone marrow: 100% cellularity, almost all promyelocytes
Acute Promyelocytic Leukemia
-First described in 1957: “a very rapidly fatal course of only a few weeks duration, a white blood cell picture dominated by promyelocytes, and a severe bleeding tendency due to fibrinolysis and thrombocytopenia”
-”seems to be the most malignant form of acute leukemia”
APLMost impressive features of APL:-occurence of a severe bleeding diathesis :up to 20-30% of patients died rapidly due
to cerebral hemorrhage-large numbers of promyelocytic
malignant cells found in marrow and peripheral blood with folded nuclei, azurophilic granules and Auer rods
1976: FAB nomenclature committee: M3
APL
-accounts for 10-15% of cases of AML
-sometimes occurs after cytoxic treatment for other malignancies
-median age 30; does occur in children and elderly
APLClinical management difficult because of
the unpredictable onset of life threatening bleeding disorders; chemo exacerbates the bleeding diathesis.
2 major causes of bleeding: thrombocytopenia and fibrinogenopenia
DIC vs primary fibrinolysis, or both?Features of both exist; etiology is unclear
but 2 tumor cell procoagulants may be implicated
APL
Genetic abnormalities:-identified in the early 1980s:
balanced translocation in long arms of chromosomes 15 and 17
t (15;17)
APL
Prognostic factors: intensity of thromobocyopenia, number of WBCs
Low risk: WBC less than 10K plts greater than 40K
Intermediate risk: WBC less than 10K plts less than 40K
High risk: WBC greater than 10K
APLTreatment initially: anthracyclines and
platelet transfusions-main causes of poor outcome: failure to
achieve remission due to resistance to chemo, and fatal hemorrhage
By 1988: early mortality due to bleeding 15%, failure to enter remission 10%= 75% initial remission rate
Relapse rate within 2 years: 35% = approximately 30-35% 2 yr survival rate
APL
SCIENCE MARCHES ON!Concept: certain agents can trigger a
differentiating process in leukemic cells:malignant changes are not irreversible.
-more than 100 hundred agents found that could induce terminal differentiation for certain types of cells
APL
In APL, all trans retinoic acid (ATRA) was found to be the most effective in vitro
BUT: not available in Europe or US
APLThe Chinese Connection:1985: Chinese researcher begins working
with a French researcher in APL, resulting in a close collaboration between Paris and Shanghai, where ATRA could be manufactured.
First patients treated in Shanghai with ATRA in 1987:
No worsening of bleeding diathesis (as with chemo)
Up to 95% remission rate!
APL
1989: Tienammen Square; cessation of Franco-Sino cooperation
-Roche agrees to make drug but only for French patients; trials begin in France.
APLMore science: -retinoic acid receptor alpha (RARA)
located on long arm of chromosome 17-APL: abnormal RARA receptor gene
(called PML-RARA)Conclusion: APL is due to the fusion gene
PML-RARA and manufacture of protein PML-RARA which represses the normal job of RARA in myeloid differentiation
APL
ATRA trials: very favorable results BUT: rapid relapse after remissionMost favorable results: ATRA +
chemoBy 1992: treatment of APL without
ATRA considered ‘unethical’
APL
Problems with treatment:1. ATRA syndrome (aka RAS, LAS):
fever, respiratory distress, 3rd spacing, renal failure; up to 25% of patients
2. Secondary resistance to ATRA: usually reverses after 6-12 months. Due to increase in cytochrome p450 catabolism of ATRA
APL
ARSENIC?
1995: Chinese researchers investigating arsenic treatment for various cancers find effectiveness in APL.
-not useful as first line because of toxicity issues, but now can be used in relapse
APLCurrent treatment recommendations: ATRA x 3-4, then add anthracycline til
remissionConsolidation tx: at least 2 courses of
anthracycline, plus maintance ATRAFollow PCR for PML-RARA: positive result
predicts relapse (follow for up to 5 years)Arsenic is indicated for relapsed patients,
especially when treated with ATRA in past 12 months
Relatively poor results with bone marrow trans
APL
Relapse occurs in 20-30% of patients, with rate dependent on risk levels initially (WBCs, platelets):
Low risk: 98% 3 year relapse free survival
Intermediate: 89%High: 70%
APL
Conclusions:-APL went from being “the most
malignant form of leukemia” to being curable in at least 75% of patients
-’the first model of a malignant disease to be treated by drugs targeted on an oncogenic event that alters the biologic process of the diseased cells’
APL
More to come? Other leukemias may be targeted in the same way
:Gleevec for CML
Selected references:Degos, L. The History of Acute Promyelocytic
Leukemia. British Journal of Haematology, 2003, 122:539-553
-reads like a detective story!Tallman,M et al. Acute Promyelocytic
leukemia: evolving therapeutic strategies. Blood, 2002, 99:759-767
Au, W et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood,102:407-408
top related